𝙉𝙚𝙬! Important research about prescription drug use and spending. Check out the latest 𝘿𝙖𝙩𝙖𝙋𝙤𝙞𝙣𝙩𝙨 from the Health Policy Commission as well as CHIA's #tableau data dashboard and 𝘿𝙧𝙞𝙫𝙚𝙧𝙨 𝙤𝙛 𝘾𝙤𝙢𝙢𝙚𝙧𝙘𝙞𝙖𝙡 𝙋𝙧𝙚𝙨𝙘𝙧𝙞𝙥𝙩𝙞𝙤𝙣 𝘿𝙧𝙪𝙜 𝙎𝙥𝙚𝙣𝙙𝙞𝙣𝙜 interactive information at https://lnkd.in/enC94U4s #healthcare #prescriptions #pharmaceuticals #research #data
Explore the new Health Policy Commission DataPoints: Blockbuster GLP-1 Weight-Loss Drugs in Massachusetts. HPC research projects Massachusetts commercial spending on blockbuster GLP-1 weight loss drugs to surpass $270 million in 2023, more than double 2022 spending. Alongside increasing prices for these drugs are increasing prescriptions -- in just the first nine months of 2023, 3.2% of Massachusetts commercial members were prescribed a GLP-1 drug, a 7-fold increase compared to 2018. Explore the interactive data dashboards to learn more about the use and spending impacts of GLP-1 drugs in Massachusetts and nationally, patient experience findings, variation in payer coverage, and future projections for this increasingly popular class of drugs: https://lnkd.in/erfDAXFt #Healthcare #HealthPolicy #Pharmaceuticals #WeightLossDrugs #GLP1 #HealthEquity